EWG Elevate Inc. purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 791 shares of the biopharmaceutical company’s stock, valued at approximately $57,000.
Several other large investors have also made changes to their positions in BMY. New Millennium Group LLC acquired a new stake in Bristol-Myers Squibb in the second quarter valued at approximately $31,000. Clear Investment Research LLC acquired a new stake in Bristol-Myers Squibb in the third quarter valued at approximately $36,000. Western Pacific Wealth Management LP boosted its position in Bristol-Myers Squibb by 878.6% in the third quarter. Western Pacific Wealth Management LP now owns 548 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 492 shares in the last quarter. McClarren Financial Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the third quarter valued at approximately $41,000. Finally, Heritage Wealth Management LLC bought a new position in shares of Bristol-Myers Squibb during the second quarter valued at $44,000. Institutional investors and hedge funds own 75.51% of the company’s stock.
Wall Street Analysts Forecast Growth
BMY has been the subject of several analyst reports. Jefferies Financial Group initiated coverage on shares of Bristol-Myers Squibb in a research note on Monday, March 6th. They set a “hold” rating and a $62.00 price target for the company. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 3rd. Atlantic Securities raised their price target on shares of Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, February 3rd. Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “underweight” rating in a research note on Friday, February 3rd. Finally, Cantor Fitzgerald began coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, January 17th. They set an “overweight” rating and a $95.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.69.
Bristol-Myers Squibb Stock Down 0.8 %
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last issued its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.71 by $0.11. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. The firm had revenue of $11.41 billion during the quarter, compared to analysts’ expectations of $11.20 billion. During the same period last year, the company earned $1.83 earnings per share. The business’s revenue was down 4.8% on a year-over-year basis. On average, equities research analysts forecast that Bristol-Myers Squibb will post 8.07 EPS for the current fiscal year.
Bristol-Myers Squibb Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Investors of record on Monday, April 10th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 3.43%. The ex-dividend date of this dividend is Thursday, April 6th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 77.29%.
Insider Buying and Selling
In related news, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now directly owns 23,043 shares in the company, valued at $1,721,081.67. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Bristol-Myers Squibb news, EVP Ann Powell sold 11,183 shares of Bristol-Myers Squibb stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total value of $835,258.27. Following the sale, the executive vice president now owns 23,043 shares of the company’s stock, valued at $1,721,081.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Giovanni Caforio sold 240,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the completion of the sale, the chief executive officer now directly owns 236,104 shares in the company, valued at approximately $17,625,163.60. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.
About Bristol-Myers Squibb
Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.